- Roman Fischer of Oxford University demonstrates
high-throughput 4D proteomics on non-depleted, untreated plasma
identifying >350 protein groups with short 10-20 minute methods,
enabling high throughput, robust biomarker discovery
- OmicEra Diagnostics reports running 720 undepleted serum
samples from 31 COVID-19 patients over just 12 days on a single
timsTOF Pro system at a rate of 60 samples/day, with 502 proteins
quantified and 116 proteins with significant changes in expression
levels
- TIMS/PASEF processing of plasma samples with the Seer
Proteograph™ Product Suite yields unprecedented depth, speed, and
scalability, with the identification of >1,700 protein
groups
- PaSER software version 1.1 released, including performance
enhancements and visualization of Mobility-Offset Mass-Aligned
(MOMA) analysis in 4D proteomics
- Enrichable PhoX cross-linker and three cleavable
cross-linkers launched, analysis of timsTOF cross-linking data to
be supported in MaxQuant and XlinkX for structural proteomics and
protein-protein interaction (PPI) research
At the virtual 17th US HUPO Conference (US HUPO 2021), Bruker
Corporation (Nasdaq: BRKR) today announces progress with several
collaborations in deep, unbiased plasma proteomics, leveraging the
speed, sensitivity and dynamic range of 4D proteomics on timsTOF
Pro systems.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210308005537/en/
Fig 1: Large-scale peptide CCS
measurement with TIMS and PASEF.
www.nature.com/articles/s41467-021-21352-8 (Photo: Business
Wire)
New results from a key collaborator, Professor Kirk Hansen of
the University of Colorado Anschutz Medical Center, will be
presented at Bruker’s virtual seminar at US HUPO on Tuesday, March
9th at 2:00 p.m. EST. Registration for the US HUPO Conference is
required to attend the event live. Dr. Hansen will present studies
of the plasma proteomes of patients infected with COVID-19, as well
as a large-cohort comparison of plasma proteome changes in trauma
patients.
Dr. Hansen’s research reveals protein dynamics in acute injury
and disease states with tens of thousands of measurements per
sample. Running larger clinical cohorts is illuminating molecular
relationships and mechanistic understanding that has the potential
to go well beyond current diagnostics.
Professor Hansen commented: “We have only recently re-entered
the plasma proteomics space, primarily because of the speed,
sensitivity and throughput of the timsTOF Pro. Coupled with the
Evosep One, this system is providing the reliability and throughput
that we could not achieve just a few years ago.”
In early 2021, Bruker announced a breakthrough paper by the
Mann-group that demonstrates unbiased, quantitative true
single-cell proteomics to address important questions in
single-cell biology and pathobiology
(www.biorxiv.org/content/10.1101/2020.12.22.423933v1). Bruker
intends to launch a high-end, dedicated single-cell timsTOF system
in early 2022 for unbiased, quantitative single-cell
proteomics.
Bruker recently announced a new Nature Communications
publication by the Mann & Theis groups on the benefits of
large-scale peptide Collisional Cross Section (CCS) measurements
and machine learning for 4D proteomics (
doi.org/10.1038/s41467-021-21352-8). Harnessing deep learning, CCS
values can now be predicted for any peptide from any organism,
forming a basis for advanced 4D proteomics workflows that make full
use of the additional peptide CCS 4th dimension.
A. PaSER 1.1 Real-Time Proteomics Search
Bruker releases its PaSER software v.1.1, which Dr. Chris
Adams, Director of Proteomics Business Development at Bruker
Daltonics, will present during the US HUPO seminar on March 9th.
PaSER is GPU-based and enables proteomics database search in real
time, building on Bruker’s acquisition of IP2 software.
‘PaSER’ stands for Parallel Search Engine in
Real-time, with parallelized, multi-threaded searches on
GPUs to obtain results typically faster than the data acquisition.
This allows ‘run & done’ high-throughput 4D proteomics with
identified peptides and protein groups available as soon as the
experiment is complete.
In addition to performance enhancements, PaSER 1.1 includes
visualization of 4D data, including MOMA features and search
results. A powerful feature of 4D proteomics is Mobility-Offset
Mass-Aligned (MOMA) analysis, where co-eluting isomeric or isobaric
ions, which cannot be distinguished in typical 3D proteomics, are
resolved by mobility separation with precise Collision Cross
Sections (CCS) at scale.
B. Cross-Linking for Structural Proteomics and
Protein-Protein Interactions (PPIs)
Bruker announces the release of new consumables and software for
chemical cross-linking of proteins (XL-MS) for the study of protein
structure and interactions. The PhoX cross-linker, licensed from
the University of Utrecht after development by the groups of Albert
Heck and Richard Scheltema, will be commercially available from
Bruker this spring. PhoX is an enrichable cross-linker with a
phosphonate group that allows purification from the complex
mixtures resulting from XL-MS reactions, using metal-bead affinity
purification. Such enrichment greatly enhances the ability to
detect cross-linked peptides, and collaborative work between the
groups of Albert Heck, Richard Scheltema and Bruker has shown that
cross-link detection can be enhanced by TIMS separation using
caps-PASEF (MCP, 20 Jul 2020, 19(10):1677-1687). Bruker will
also launch 3 cleavable cross-linkers in the spring, which are
preferred by some research groups, as cleavage of cross-linkers in
MS/MS experiments results in characteristic mass differences that
are easily detected.
Chemical crosslinking data is very complex and automated
analysis software is required. A new version of the popular
MaxQuant software from the group of Professor Juergen Cox at the
Max Planck Institute in Martinsried, Germany, also supports the
analysis of XL-MS data from timsTOF Pro systems. It is in
beta-test, expected to be released in April 2021 to take advantage
of 4D proteomics for XL-MS work.
C. Progress in Deep, Unbiased Plasma Proteomics
Several research groups have recently presented exciting results
on plasma proteomics using a variety of methods.
In February 2021, Professor Roman Fischer of the Target
Discovery Institute in the Nuffield Department of Medicine at
Oxford University presented “High-Throughput Proteomics During a
Pandemic” at Genetic Engineering & Biotech News
(genengnews.com). Dr. Fischer discusses high-throughput 4D
proteomics of several hundred undepleted plasma samples from
COVID-19 patients with different disease severity, healthy controls
and patients suffering from other pathologies, like sepsis.
Also in February 2021, researchers from OmicEra Diagnostics GmbH
in Planegg, Germany, posted a manuscript on MedRxiv
“High-resolution longitudinal serum proteome trajectories in
COVID-19 reveal patients-specific seroconversion”, in which 31
patients were followed longitudinally for an average of 31 days,
using high-throughput 4D proteomics. This study employed OmicEra´s
automated proteomics pipeline coupled with the Evosep One
chromatography system running 21 minute gradients to achieve
throughput of 60 samples per day.
Using this methodology, 720 undepleted serum samples were run by
OmicEra over 12 days on a single timsTOF Pro, with a total of 502
proteins quantified. Some 116 proteins had quantitative changes in
expression levels. At US HUPO, Bruker releases an application note
on serum proteomics on our collaborative work with OmicEra.
At US HUPO 2021, Seer (www.seer.bio) will present a
collaborative poster with Bruker, showing the unique capabilities
of Seer’s engineered nanoparticles in combination with the
TIMS/PASEF methods. Together, this strategy achieved unbiased, deep
and rapid plasma proteome analysis with >1,700 protein groups
identified with 90-minute DDA nanoLC-TIMS-MS/MS methods. The
combination of Seer’s Proteograph Product Suite with the TIMS/PASEF
method provides a scalable solution for unbiased and deep
proteomics, accessible to nearly any lab, for the first time.
Dr. Chris Adams, Director of Proteomics Business Development at
Bruker Daltonics, stated: “It has been rewarding to see the recent
rapid advances in the field of plasma proteomics, an area we expect
to grow rapidly in liquid biopsy multiomics translational research
and biomarker validation. These advances in deep, unbiased plasma
proteomics are enabled by the throughput, robustness and unique 4D
proteomics selectivity and sensitivity advantages of TIMS/PASEF
methods.”
Links to Bruker events at the virtual US HUPO conference 2021
can be found here:
https://www.bruker.com/en/landingpages/bdal/us-hupo.html.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210308005537/en/
Media Contact: Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E: petra.scheffer@bruker.com
Investor Contact: Miroslava Minkova Director of Investor
Relations & Corporate Development T: +1 (978) 663-3660, ext.
1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024